Neang L. Email & Phone Number

Redwood City, California, United States

Alameda County, California, United States

Alameda County, California, United States

Clinical Pharmacology and Pharmacometrics lead for cabozantinib. Overseeing all the cabozantinib pivotal studies, ER analysis for safety and efficacy, and authoring the summary of clinical pharmacology to support sNDA for mono- and combination therapy.

Non-clinical, clinical pharmacology, and M&S project lead for Ophthalmology, Oncology, and CVRM.

South San Francisco

Work as clinical pharmacology, pharmacometrics project lead to support multiple projects from pre-clinical antibody engineering to clinical phases of drug development • Author for PK section of IND, Investigator’s Brochure, Clinical Study Report, pre-IND briefing document, end of phase 2 briefing documents• Assist teams with affinity goal setting for antibody/Fab, translational modeling, selecting FTIH, phase 2, and phase 3 doses

South San Francisco

Mountain View Ca

Provide PKPD analysis and clinical pharmacology support for multiple projects ranging from early discovery to late clinical stages within the Inflammation, Immunology & Oncology, CVMD, and oncolytic virus therapeutic areas. Key responsibilities include:- Developing mechanistic PK/PD models to determine feasibility of target selection and guide antibody protein engineer group to optimize antibody affinity.- Designing in vitro and in vivo studies using model-based approaches to fill existing knowledge gaps that enables discovery teams to make go/no-go decisions.- Collaborate with toxicologists and project teams to design PKPD and GLP tox studies using model-based approaches.-Principle investigator for TK sub-reports in GLP tox studies.-Responsible for writing and reviewing nonclinical section of INDs filing-Using PK/PD modeling to provide dose rational and efficacious dose projections for FIH studies-Using PK/PD modeling to provide dose rationale for adult, Japanese and adolescent population-Contributing to briefing document preparation for pre-INDs, and the EOP 2 meeting

Buffalo, New York, United States

South San Francisco, Ca

Developing a clinical viral dynamic modeling to describe the time-course of viral dynamic in a challenge study based on literature data. The final model was used to conduct the clinical trial simulations to determine the clinical measurement for challenge study after treatment of in-house compound.

Phd

Bs (Hon)